Many adults aged 60-plus plan to take steps to avoid flu but not other potentially preventable diseases such as shingles
8 October 2013 | By Merck
The survey revealed the importance of physicians and pharmacists in encouraging vaccination...
List view / Grid view
News
Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial
8 October 2013 | By Boehringer Ingelheim
"These results are promising particularly because they show the potential to evaluate harder-to-treat populations..."
Janssen acquires investigational NS5A inhibitor for the treatment of Hepatitis C from GlaxoSmithKline
8 October 2013 | By Janssen Pharmaceuticals, Inc
"We're excited to add GSK2336805 to our existing portfolio of direct-acting antivirals (DAAs)...
Simeprevir Data from COSMOS study in Hepatitis C Patients accepted as late-breaking presentation at the annual meeting of the American Association for the Study of Liver Diseases (AASLD)
8 October 2013 | By Johnson & Johnson
Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells...
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
8 October 2013 | By GlaxoSmithKline
These latest results demonstrated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases...
Tecan Academy launched in Europe
8 October 2013 | By Tecan
Tecan announces the European launch of its Tecan Academy web-based training tool...
Ben Venue Laboratories, Inc. to cease production
7 October 2013 | By Boehringer Ingelheim Corp
Ben Venue Laboratories, Inc has decided to cease production by the end of 2013...
MedImmune Completes Acquisition of Amplimmune
7 October 2013 | By AstraZeneca
As previously announced, the acquisition bolsters MedImmune’s oncology pipeline...
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
Intel and Janssen Pharmaceutica to collaborate with imec and 5 Flemish universities to open ExaScience Life Lab
7 October 2013 | By Mengele PMC
Lab will allow development of even more powerful supercomputers for life sciences research...
Janssen launches new initiative to drive health policy debate
7 October 2013 | By Publicis Life Brands Resolute
Multi-stakeholder collaboration at the heart of Janssen Health Policy Centre...
European health R&D investments stagnate for the first time in history Private industry invests 29 bln € in health R&D, and public authorities 18 bln €
7 October 2013 | By Publicis Life Brands Resolute
New report presents unique statistics on health R&D in the European Union...
The Nobel Prize in Physiology or Medicine 2013
7 October 2013 | By Nobel Prize
The 2013 Nobel Prize honours three scientists who have solved the mystery of how the cell organizes its transport system...
Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU
5 October 2013 | By Novartis
"The positive new data clearly show the potential of omalizumab to treat CSU, a disease where more than 50% of patients don't respond..."
New data presented at 29th ECTRIMS Congress reinforce the clinical profile of investigational laquinimod on disease progression and inflammation in relapsing-remitting multiple sclerosis
4 October 2013 | By Teva Pharmaceutical Industries Ltd
Pooled data analysis of Phase III ALLEGRO and BRAVO studies add to our understanding of investigational laquinimod for relapsing-remitting Multiple Sclerosis...
